We are live on ! Find out more
ATRA icon

Atara Biotherapeutics
ATRA

32 hedge funds and large institutions have $13.9M invested in Atara Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $12.4M → $13.9M (+$1.53M)

5.36% less ownership

Funds ownership: 35.61% → 30.25% (-5.4%)

14% less funds holding

Funds holding: 37 → 32 (-5)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
32
Holders Change
-5
Holders Change %
-13.51%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
6
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$309K
2
Citadel Advisors
Citadel Advisors
Florida
+$168K
3
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$164K
4
BlackRock
BlackRock
New York
+$73.3K
5
Raymond James Financial
Raymond James Financial
Florida
+$29.3K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$1.31M
2
TCM
Tang Capital Management
California
-$447K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$365K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$244K
5
BC
Birchview Capital
Vermont
-$131K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$1.67K – – –
RBI
27
Raiffeisen Bank International
Austria
$1.54K – – –
BT
28
Banque Transatlantique
France
$1.37K – – –
RhumbLine Advisers
29
RhumbLine Advisers
Massachusetts
$1.35K – – –
Group One Trading
30
Group One Trading
Illinois
$1.14K – – –
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$386 – – –
Osaic Holdings
32
Osaic Holdings
Arizona
$77 – – –
TCM
33
Tang Capital Management
California
– -$447K -75,196 Closed
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
– -$244K -41,014 Closed
BC
35
Birchview Capital
Vermont
– -$131K -22,000 Closed
SW
36
SVB Wealth
Massachusetts
– -$2.5K -421 Closed
Lazard Asset Management
37
Lazard Asset Management
New York
– -$2K -368 Closed
Russell Investments Group
38
Russell Investments Group
United Kingdom
– -$2.19K -368 Closed
TRCT
39
Tower Research Capital (TRC)
New York
– -$1.1K -185 Closed
IA
40
IFP Advisors
Florida
– -$1.07K -180 Closed
Barclays
41
Barclays
United Kingdom
– -$6 -1 Closed
1
2

ATRA Hedge Fund Activity: Q2 2025 in Review

32 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2025, worth a combined $13.9M — up 12% from $12.4M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ATRA and 4 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.

The largest buyer was Marshall Wace, opening a new position worth an estimated $309K. The largest seller was Bank of America, cutting an estimated $1.31M.

  • 32 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2025, down from 37 in Q1 2025.
  • Funds reported $13.9M of Atara Biotherapeutics stock for Q2 2025, up 12% quarter-over-quarter.
  • 4 funds opened new Atara Biotherapeutics positions in Q2 2025 and 9 closed out, a net change of -5 holders.
  • The largest Atara Biotherapeutics buyer in Q2 2025 was Marshall Wace, an estimated $309K added.
  • The largest Atara Biotherapeutics seller in Q2 2025 was Bank of America, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2025.